Grufity logoGrufity logo

CRISPR Therapeutics AG Stock Research

CRSP

43.43USD+0.29(+0.67%)Market Closed

Market Summary

USD43.43+0.29
Market Closed
0.67%

CRSP Alerts

CRSP Stock Price

CRSP RSI Chart

CRSP Valuation

Market Cap

3.4B

Price/Earnings (Trailing)

-5.24

Price/Sales (Trailing)

2.8K

EV/EBITDA

-5.11

Price/Free Cashflow

-6.4

CRSP Price/Sales (Trailing)

CRSP Profitability

EBT Margin

-54298.83%

Return on Equity

-34.67%

Return on Assets

-28.99%

Free Cashflow Yield

-15.63%

CRSP Fundamentals

CRSP Revenue

Revenue (TTM)

1.2M

Revenue Y/Y

-99.95%

Revenue Q/Q

-93.62%

CRSP Earnings

Earnings (TTM)

-650.2M

Earnings Y/Y

21.72%

Earnings Q/Q

36.65%

Price Action

52 Week Range

38.9486.95
(Low)(High)

Last 7 days

-4.3%

Last 30 days

-13.8%

Last 90 days

-1.5%

Trailing 12 Months

-32.6%

CRSP Financial Health

Current Ratio

15.3

CRSP Investor Care

Shares Dilution (1Y)

1.98%

Diluted EPS (TTM)

-8.36

Peers (Alternatives to CRISPR Therapeutics AG)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
127.1B
26.3B
0.79% 2.78%
19.4
4.83
1.32% 11.18%
99.8B
27.3B
-4.19% 39.66%
21.72
3.66
-0.09% -26.23%
58.1B
19.3B
-4.61% -16.03%
6.95
3.02
4.29% -31.47%
39.0B
10.2B
-0.92% 26.77%
12.8
3.83
-7.36% 95.80%
MID-CAP
9.4B
1.5B
-5.59% 3.19%
60.62
6.29
31.34% 72.43%
3.1B
108.5M
-21.66% -32.82%
-9.55
28.71
122.90% -12.19%
2.2B
107.9M
21.83% 38.60%
-4.63
20.79
54.84% 17.36%
2.2B
60.9M
-25.55% -48.21%
-7.49
35.56
17.51% 22.00%
SMALL-CAP
1.3B
112.0M
-7.70% -49.25%
-4.81
11.47
-70.76% -603.77%
1.1B
7.0M
-17.00% 22.02%
-7.14
159.78
131.81% -45.39%
524.4M
96.3M
-14.58% -86.07%
-1.86
5.45
72.44% -32.79%
519.7M
2.0B
-33.63% -92.58%
-0.79
0.26
72.89% 62.27%
276.9M
111.3M
-42.96% -71.96%
-1.44
2.49
0.54% -7.86%
101.6M
107.0K
-17.23% -85.52%
-0.94
949.93
-88.00% -52.91%
26.0M
-
40.00% -84.44%
-0.32
3.21
0.51% -185.61%

Financials for CRISPR Therapeutics AG

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-99.5%1,198,000229,639,250458,080,500686,521,750914,963,000
Operating Expenses-3.9%674,359,000701,409,000648,600,000603,265,000541,435,000
  S&GA Expenses-2.4%102,464,000104,973,000101,681,000104,214,00099,690,000
  R&D Expenses0.1%461,645,000461,185,000428,063,000387,172,000340,567,000
EBITDA3.5%-626,328,000-649,363,000-601,681,000337,710,000-
EBITDA Margin-18388.6%-522-2.83-0.66--
Earnings Before Taxes3.5%-650,500,000-673,950,000-626,574,000316,510,000379,531,000
EBT Margin-18401.6%-542-2.93-0.68--
Net Income4.5%-650,175,000-680,848,000-633,452,000311,607,000377,661,000
Net Income Margin-18205.0%-542-2.96-0.69--
Free Cahsflow-4.8%-532,929,000-508,631,000-515,774,000414,365,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-4.7%2,2432,3532,4632,6062,752
  Current Assets-4.1%1,8531,9332,1072,2612,418
    Cash Equivalents-57.1%212494497684923
  Net PPE-1.5%164166165157138
Liabilities-8.0%368399373361352
  Current Liabilities-19.7%121151120114120
Shareholder's Equity-4.0%1,8751,9542,0912,2452,399
  Retained Earnings-15.0%-846-735-560-375-195
  Additional Paid-In Capital0.9%2,7352,7092,6702,6352,598
Accumulated Depreciation-45.3%28.0051.0044.0038.00-
Shares Outstanding0.3%79.0078.0078.0077.0077.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-5.8%-495-468-444504539
  Share Based Compensation-2.9%98.00101103106102
Cashflow From Investing-181.6%-258-91.84-744-982-1,035
Cashflow From Financing-9.0%39.0042.0038.0036.00251

Risks for CRSP

What is the probability of a big loss on CRSP?

100%


Probability that CRISPR Therapeutics AG stock will be more than 20% underwater in next one year

88.1%


Probability that CRISPR Therapeutics AG stock will be more than 30% underwater in next one year.

80%


Probability that CRISPR Therapeutics AG stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CRSP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if CRISPR Therapeutics AG was unfortunately bought at previous high price.

Drawdowns

Returns for CRSP

Cumulative Returns on CRSP

-3.9%


5-Year Cumulative Returns

0.6%


3-Year Cumulative Returns

What are the long-term rolling returns for CRSP?

FIve years rolling returns for CRISPR Therapeutics AG.

Annualized Returns

Which funds bought or sold CRSP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-17.56
-257,125
269,875
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
sold off
-100
-313,000
-
-%
2023-03-10
BAILLIE GIFFORD & CO
reduced
-8.73
-8,151,780
10,705,200
0.01%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-15.37
-2,952,000
3,283,000
0.02%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
25,813
25,813
-%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
reduced
-50.85
-93,740
41,260
0.02%
2023-02-28
Voya Investment Management LLC
added
1.23
-529,457
899,543
-%
2023-02-24
SRS Capital Advisors, Inc.
sold off
-100
-3,000
-
-%
2023-02-21
Boulder Wealth Advisors, LLC
new
-
8,000
8,000
0.01%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
reduced
-39.03
-90,554
55,446
-%

1–10 of 42

Latest Funds Activity

Are funds buying CRSP calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own CRSP
No. of Funds

CRISPR Therapeutics AG News

Yahoo Eurosport UK

CRISPR Therapeutics AG's (NASDAQ:CRSP) latest 5.1% decline adds to one-year losses, institutional investors may consider drastic measures.

Yahoo Eurosport UK,
40 hours ago

Zacks Investment Research

Nasdaq

U.S News & World Report Money

7 Top Gene-Editing Stocks to Buy | Investing | U.S. News.

U.S News & World Report Money,
16 days ago

Schedule 13G FIlings of CRISPR Therapeutics AG

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital international investors
7.1%
5,560,492
SC 13G
Feb 03, 2023
sumitomo mitsui trust holdings, inc.
5.11%
4,006,476
SC 13G/A
Feb 14, 2022
nikko asset management americas, inc.
5.64%
4,319,471
SC 13G/A
Feb 11, 2022
capital international investors
4.8%
3,706,004
SC 13G/A
Feb 09, 2022
ark investment management llc
11.88%
9,087,868
SC 13G/A
Feb 04, 2022
sumitomo mitsui trust holdings, inc.
5.64%
4,319,471
SC 13G/A
Sep 10, 2021
ark investment management llc
10.03%
7,644,350
SC 13G/A
Aug 10, 2021
capital international investors
5.6%
4,265,002
SC 13G/A
Feb 16, 2021
ark investment management llc
14.62%
10,412,976
SC 13G/A
Feb 16, 2021
capital international investors
10.7%
7,626,355
SC 13G/A

CRSP Fair Value

CRISPR Therapeutics AG fair value in different scenarios

The table shows the Fair Value estimates for CRISPR Therapeutics AG for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

7.65

-82.39%

8.24

-81.03%

10.03

-76.91%

12.82

-70.48%

17.78

-59.06%
Current Inflation

7.53

-82.66%

8.04

-81.49%

9.62

-77.85%

12.04

-72.28%

16.32

-62.42%
Very High Inflation

7.37

-83.03%

7.80

-82.04%

9.12

-79.00%

11.10

-74.44%

14.60

-66.38%

Historical CRISPR Therapeutics AG Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of CRISPR Therapeutics AG

View All Filings
Date Filed Form Type Document
Mar 14, 2023
3
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
8-K
Current Report
Mar 01, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading

Latest Insider Trading transactions for CRSP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-13
Kulkarni Samarth
sold (taxes)
-408,170
43.22
-9,444
chief executive officer
2023-03-13
KASINGER JAMES R.
sold (taxes)
-99,622
43.22
-2,305
general counsel and secretary
2023-03-11
KASINGER JAMES R.
acquired
-
-
2,250
general counsel and secretary
2023-03-11
Kulkarni Samarth
acquired
-
-
9,000
chief executive officer
2023-03-10
KASINGER JAMES R.
acquired
-
-
2,833
general counsel and secretary
2023-03-10
Kulkarni Samarth
acquired
-
-
11,833
chief executive officer
2023-02-27
Kulkarni Samarth
acquired
478,000
19.12
25,000
chief executive officer
2023-02-27
Kulkarni Samarth
sold
-1,206,240
48.2497
-25,000
chief executive officer
2023-02-21
Smith Brendan
sold (taxes)
-67,177
48.26
-1,392
chief financial officer
2023-02-21
Kulkarni Samarth
sold (taxes)
-307,561
48.26
-6,373
chief executive officer

1–10 of 50

Samarth Kulkarni
470
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRSP Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:   
Total revenue$ 1,198$ 914,963$ 719
Operating expenses:   
Research and development461,645340,567221,382
General and administrative102,46499,69085,747
Collaboration expense, net110,250101,17848,025
Total operating expenses674,359541,435355,154
(Loss) income from operations(673,161)373,528(354,435)
Other income   
Other income, net22,6616,0036,379
Total other income, net22,6616,0036,379
Net income (loss) before income taxes(650,500)379,531(348,056)
Benefit (provision) for income taxes325(1,870)(809)
Net (loss) income(650,175)377,661(348,865)
Foreign currency translation adjustment(80)(11)40
Unrealized loss on marketable securities(10,500)(4,973)(130)
Comprehensive (loss) income$ (660,755)$ 372,677$ (348,955)
Net (loss) income per common share - basic$ (8.36)$ 4.97$ (5.29)
Basic weighted-average common shares outstanding77,746,57575,948,68665,949,672
Net (loss) income per common share - diluted$ (8.36)$ 4.70$ (5.29)
Diluted weighted-average common shares outstanding77,746,57580,393,49665,949,672
Collaboration Revenue [Member]   
Revenue:   
Total revenue$ 436$ 913,081$ 543
Grant Revenue [Member]   
Revenue:   
Total revenue$ 762$ 1,882$ 176

CRSP Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 211,885$ 923,031
Marketable securities1,603,4331,456,098
Accounts receivable0305
Prepaid expenses and other current assets37,70838,079
Total current assets1,853,0262,417,513
Property and equipment, net163,634137,575
Marketable securities, non-current53,1300
Intangible assets, net71125
Restricted cash11,63516,913
Operating lease assets156,921174,460
Other non-current assets4,6405,291
Total assets2,243,0572,751,877
Current liabilities:  
Accounts payable27,42814,816
Accrued expenses77,68291,003
Deferred revenue, current01,011
Accrued tax liabilities135724
Operating lease liabilities15,84212,158
Other current liabilities20171
Total current liabilities121,107119,883
Deferred revenue, non-current12,32312,323
Operating lease liabilities, net of current portion228,179212,872
Other non-current liabilities5,9697,339
Total liabilities367,578352,417
Commitments and contingencies (Note 9)
Shareholders’ equity:  
Common shares, CHF 0.03 par value, 150,347,467 and 145,364,335 shares authorized at December 31, 2022 and 2021, respectively, 78,692,766 and 77,170,382 shares issued at December 31, 2022 and 2021, respectively, 78,512,450 and 76,990,066 shares outstanding at December 31, 2022 and 2021, respectively.2,4412,391
Treasury shares, at cost, 180,316 shares at December 31, 2022 and 2021, respectively(63)(63)
Additional paid-in capital2,734,8382,598,114
Accumulated deficit(846,090)(195,915)
Accumulated other comprehensive loss(15,647)(5,067)
Total shareholders’ equity1,875,4792,399,460
Total liabilities and shareholders’ equity$ 2,243,057$ 2,751,877